The AZILECT Media Center, your resource for the latest information about AZILECT and Parkinson’s disease.

Here you will find the latest News Releases and Fact Sheets related to AZILECT and Parkinson's disease.

If you are a member of the media and would like to speak with someone about Parkinson's disease or AZILECT, please contact:


Denise Bradley
Teva USA
215-591-8974
Denise.Bradley@tevapharm.com



Please note this contact is for media inquiries only.


 

AZL111023557/111692

 

AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of Parkinson’s disease (PD) both as initial therapy alone and to be added to levodopa later in the disease.

IMPORTANT SAFETY INFORMATION ABOUT AZILECT

Do not take Azilect if you are taking meperidine as it could result in a serious reaction such as coma or death. Also, do not take Azilect with tramadol, methadone, propoxyphene, dextromethophran, St. John’s wort, or cyclobenzaprine. You also should not take Azilect with other monoamine oxidase inhibitors (MAOIs).

Inform your physician if you are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and ciprofloxacin. If you have moderate to severe liver disease, you should not take Azilect. You should not exceed a dose of 1 mg per day of Azilect in order to prevent a possibly dangerous increase in blood pressure. All PD patients should be monitored for melanoma (skin cancer) on a regular basis.

Side effects seen with Azilect alone are flu syndrome, joint pain, depression, and indigestion: and when taken with levodopa are uncontrolled movements (dyskinesia), accidental injury, weight loss, low blood pressure when standing, vomiting, anorexia, joint pain, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, and fall.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

AZL101023709/101191